Background Biologic therapies have revolutionised the care of patients with psoriasis, although they come at significant extra cost. Guidance on their use in the UK National Health Service (NHS) has so far focused on patients who are ''biologic naive'', yet a minority of patients have poor response and require further treatment. Objectives To assess the potential cost effectiveness of sequential biologic therapies in patients with psoriasis who have been exposed to previous biologic therapy.
Methods A two-part model with a 10-year time horizon was built to model an initial 13.5-week ''trial'' phase and a longer-term ''treatment'' period with annual Markov cycles. Psoriasis Area and Severity Index (PASI) response rates from subgroup analyses of three randomised placebocontrolled trials evaluating biologic agents were considered. A meta-analysis of these data provided probabilities of achieving PASI response (50/75/90) in the short term, and published evidence and assumptions were used to predict outcomes over the longer term. Benefits were measured in quality-adjusted life years (QALYs), and costs to the UK NHS included drugs, administration, monitoring, and hospitalisation. Costs and benefits were discounted 3.5 % per annum. Cost effectiveness of sequential biologic therapy was measured using an incremental cost-effectiveness ratio (ICER) compared to best supportive care (BSC). Extensive sensitivity analyses were performed to assess the impact of alternative assumptions on the results. Results Results indicate that over 10 years, switching to a second biologic following intolerance to or failure of a first is likely to generate more QALYs than BSC, but at a higher cost. Base case results suggest the ICER of the second biologic compared to BSC is £17,681 per QALY; however, sensitivity analyses indicate that changes in the efficacy of BSC, drug costs, dropout rates, and rates of hospitalisation have a significant impact, causing the ICER to range from less than £10,000 to over £50,000 per QALY. Conclusions Further biologic therapy for patients with psoriasis who have previously been treated with biologic therapy may be cost effective, although there is considerable uncertainty in the results. Future studies should be designed to evaluate the clinical efficacy of biologic therapies in this subgroup with particular attention given to short-term and longer-term responses.
Introduction
Over the past decade, biologic therapies have been introduced into the treatment paradigm for psoriasis and have revolutionised the management of severe disease, with improved outcomes and reduced length of hospital stays. Three tumour necrosis factor (TNF) antagonists (adalimumab, etanercept, and infliximab) and the Interleukin 12 and 23 (IL12/23) monoclonal antibody (ustekinumab) are licensed for use in moderate to severe psoriasis.
All four agents are approved for use by the National Institute for Health and Care Excellence (NICE) in people who have failed to respond to systemic nonbiological therapies including methotrexate and ciclosporin and PUVA (psoralen combined with ultraviolet A treatment) or if the person is intolerant to, or has a contraindication to, these treatments, subject to certain disease severity criteria [which for etanercept, adalimumab and ustekinumab are a Psoriasis Area and Severity Index (PASI) score [10 and a Dermatology Life Quality Index (DLQI) [10 (severe disease) [1] [2] [3] and for infliximab, a PASI [20 and a DLQI [18 (very severe disease) [4] .
These drugs have been found to be effective and generally well tolerated in the majority of patients but have high acquisition costs. Explicit guidance from NICE on indications for use and continued use has been fundamental to ensuring equality of access to biologic therapy for people with severe or very severe disease. In a minority of people, treatment is complicated by a poor response that may be either a primary nonresponse or, more commonly, gradual attrition of response with time.
Existing NICE guidance on the use of biologic therapies in the treatment of plaque psoriasis has focused on patients assumed to be ''biologic naive'' and that those who fail therapy have no further options, and, consequently, receive only palliative care. With multiple biologic therapies now licensed, it is difficult to support the assumption that no further therapy options aside from palliative care exist following the failure of a first biologic therapy. However, due to a lack of clinical and cost-effectiveness evidence, existing guidance makes little mention of the sequential use of biologic therapies. A recent systematic review by Mauskopf and colleagues [5] found that even where treatment sequencing pathways are recommended, there is a clear lack of cost-effectiveness evidence demonstrating the value of such pathways.
Clinical experience in psoriasis, and in other inflammatory conditions such as Crohn's disease and rheumatoid and psoriatic arthritis, suggest that a second and subsequent biological drug may also be effective. However, some studies have suggested that response rates to a second biological drug may be lower than that to the first, and that even in those who do respond, the duration of response may be shortened. Clinical experience suggests that patients who fail to respond to a biological therapy are likely to have more severe psoriasis and greater health service use than the average patient eligible for these drugs.
NICE commissioned a clinical guideline to provide recommendations to health professionals in England and Wales on the assessment and treatment of patients with psoriasis [6] . With regard to biologic therapies, the scope of the guideline was limited to assessing their efficacy and safety in people with psoriasis who have already received a first biologic therapy, because this is an area in which there is variation in practice across the UK and on which clear guidance is not currently available. Here, we describe an original costeffectiveness model developed to inform recommendations around the use of biological therapy in this subgroup of patients. The objective of this analysis was to consider, as far as available evidence allows, the potential cost effectiveness of sequential use of biologic therapies in patients for whom earlier biologic therapy has failed. Given the substantial uncertainties in the evidence, a secondary objective was to explore the variables driving cost effectiveness and identify circumstances under which sequential biologic therapy might represent a cost-effective use of NHS resources.
Materials and Methods

Model Overview
The analysis evaluates the potential cost effectiveness of switching to an alternative biologic therapy compared to best supportive care (i.e., no further biologic therapy) for patients with moderate to severe psoriasis (here defined as DLQI [10) who have previously received treatment with a biologic therapy. A cost-effectiveness analysis was undertaken in accordance with the NICE reference case [7] in which benefits were measured as quality-adjusted life years (QALYs) and costs were considered from a UK National Health Service and Personal Social Services perspective and expressed in 2014 UK sterling. Healthcare costs associated with starting and maintaining biologic therapy, as well as longer-term costs of failing biologic therapy, were all included in the model. The cost effectiveness of alternative biologic therapy was assessed against a willingness-to-pay threshold of £20,000 to £30,000 per additional QALY.
The cost-effectiveness analysis must be relevant for decision making over the longer term, because most people with psoriasis can be expected to require treatment for much of their lives. However, the clinical-trial evidence for biological therapies is of short-term duration and certain assumptions were made in order to extrapolate beyond treatment initiation. A 10-year time horizon was considered sufficiently long to capture the relevant costs and benefits associated with comparators, although this was varied in sensitivity analysis. In accordance with the NICE reference case, future costs and benefits were discounted at a rate of 3.5 % per annum [7] .
The model was parameterised using best available estimates of short-term and longer-term efficacy, healthrelated quality of life, and resource use sourced from the literature. A systematic review of clinical evidence was undertaken to inform the short-term efficacy of comparators and a systematic review of economic evidence was performed to identify data relating to the resource use, costs, and benefits of different outcomes of psoriasis treatment. The economic evidence search was carried out in March 2012 in the NHS economic evaluation database (NHS EED), the Health Economic Evaluations Database (HEED), and health technology assessment (HTA) databases. In addition, the search was run on MEDLINE and Embase, with a specific economic filter, from 2008, to ensure recent publications that had not yet been indexed by these databases were identified.
Evidence of effectiveness for licensed biologic therapies, including adalimumab, etanercept, infliximab, and ustekinumab was extremely limited for this subgroup of biologic-exposed patients. In order to maximise the data available, the analysis assumed a class effect for biologic therapy and therefore pooled the results for any biologic therapy compared to placebo. The clinical data available did not allow for subgroup analyses based on the reason for failure of previous biologic therapy. Therefore, the model population includes and does not differentiate between primary nonresponders (i.e., patients who had an insufficient response to previous biologic therapy), secondary nonresponders (patients who initially responded to previous biologic therapy but lost that response over time), and patients who were intolerant to previous biologic therapy.
A two-part model was constructed in TreeAge Pro 2009 to capture the different costs and effects associated with biologic therapy and best supportive care. The structure of the model was adapted from the model developed by Woolacott and colleagues [8] , which underpinned related NICE guidance [1] and was judged by a panel of dermatologists, specialist nurses, general practioners, pharmacists, and patient representatives to reasonably reflect clinical practice (see Fig. 1 ).
The model is divided into an initial short ''trial'' period, during which all hypothetical patients receive treatment and some level of benefit from treatment, and a ''treatment'' period, during which only a subset of responders continue treatment and receive benefit (see Fig. 1 ). The initial trial period is built as a simple decision tree, with the longer-term treatment period built as a Markov model with annual cycles and half-cycle correction. During the treatment period, hypothetical patients are assumed to maintain the level of response they achieved during the trial period until they discontinue treatment or the model ends. The impact of this assumption is tested in sensitivity analysis. The model assumes no difference between treatments in terms of mortality.
Benefits
Short-Term Benefits
The predicted response rates used in the model were derived from a pairwise meta-analysis of relevant subgroup data from three randomised controlled trials (RCTs) [9] [10] [11] identified and included as part of a systematic review of published and unpublished evidence [12] . In accordance with the NICE guidelines manual [13] , a search of MED-LINE, Embase, Cinahl, and the Cochrane Library was performed in March 2012. Due to a paucity of evidence identified, unpublished evidence was sought directly from manufacturers. Details of the search terms, inclusion/ exclusion criteria, and data extractions for this review can be found in the relevant appendices of the full NICE guideline [12] .
The review identified placebo-controlled RCT evidence for infliximab [10] and ustekinumab only [14, 15] . The overall populations included in the trials were similar in terms of mean duration of disease, previous treatments, baseline PASI, and body surface area (BSA) affected, and outcomes were assessed at 11 and 12 weeks, respectively. One more RCT for which subgroup data was available compared ustekinumab with etanercept [16] , but results were not pooled with the placebo-controlled evidence. The results of this study, however, lend some support to the assumption of a biologic class effect in this population. In the subgroup with biologic exposure, no statistically significant differences were observed for ustekinumab versus etanercept at any level of PASI response [risk ratios (95 % confidence interval) at PASI50, PASI70, and PASI90 were 1.05 (0.79, 1.39), 1.5 (0.85, 2.66), and 1.88 (0.66, 5.34), respectively].
In order to incorporate a complete and coherent set of response probabilities into the model, a fixed-effects ordered probit model was used to jointly model the different trial outcomes between biologic therapies and placebo. This model has been used in previous evaluations of biological therapies in psoriasis [8, 17] . Using the ordered probit model makes efficient use of the categorical data and guarantees coherent prediction of the probability that a patient will achieve the different levels of response on scales like PASI. By contrast, if each PASI response category were analysed and incorporated as separate dichotomous outcomes, it is possible to end up with a model that makes impossible predictions, for example, that more patients experience a 75 % improvement on PASI than experience a 50 % improvement. This method, reported in greater detail by Dias and colleagues [18] , relies on two assumptions: that the treatment effects are constant across endpoints on the probit scale and that the treatment effects can be considered exchangeable between the trials. Both fixed and random effects models were used, and the deviance information criterion (DIC) statistic was used to determine the model with the best fit.
The Bayesian meta-analysis, performed in WinBUGS version 1.4 statistical software (MRC Biostatistics Unit, Cambridge, UK) using noninformative priors, provided estimates of response for an average biologic therapy based on all observed data reported for any level of PASI response. Table 1 presents the published [10] and unpublished (from PHOENIX 1 [9] and PHOENIX 2 [11] ) subgroup data from the RCTs that were included in the metaanalysis for biologic therapy compared to placebo. A burnin phase of 20,000 iterations was performed to ensure convergence. Results were based on the subsequent 80,000 iterations. For the probabilistic implementation of the economic analysis, uncertainty in the comparative treatment effect is incorporated by using a random sample of 5,000 of the simulated treatment effects, which allows us to preserve the joint posterior distribution and any observed correlations.
In terms of mean response rates generated by the metaanalysis (Table 2) , biologic therapy is superior to placebo across all levels of PASI response. Based on these
Trialperiod:
HypotheƟcal paƟents enter the model and receive a biologic therapy for an iniƟal trial period During this trial period they achieve a given percent reducƟon (50%, 75% or 90%) on the Psoriasis Area and Severity Instrument (PASI) (<PASI50, PASI50 to PASI75, PASI75 to PASI90, >PASI90) defined by the probabiliƟes pPASI00, pPASI50, pPASI75, pPASI90
Treatment period:
PaƟents who achieved a response >PASI75 during the trial period conƟnue treatment and maintain that level of response unƟl they drop out at some point in the future according to the probability pDrop Out
In accordance with NICE recommendaƟons [1] [2] [3] [4] , paƟents who achieve a response of <PASI75 during the trial period disconƟnue treatment and move immediately to best supporƟve care estimates, approximately 57 % of patients receiving biologic therapy will achieve at least a PASI75 and continue treatment after the trial period. Based on the estimates of response for placebo, regarded as representing ''best supportive care'' in the base case, benefits are expected to be very small.
Longer-Term Benefits
The evidence regarding the long-term efficacy of systemic and biologic treatments for psoriasis is growing, but still limited and very inconsistent. Several recent studies have used registry or other observational cohort data to analyse the long-term drug survival for biologics in patients with psoriasis and to identify factors that affect drug survival [19] [20] [21] [22] . The largest of these studies included 1,277 Danish patients followed for up to 10 years and included data on all four biologic drugs [19] . Their results suggest that all biologics had a shorter drug survival in patients with previous biologic exposure, but that the effect was most pronounced in ustekinumab and etanercept. Another small study found no significant differences between biologics [20] . A study focused on adalimumab found no significant difference between drug survival in biologic-naive and previously exposed patients [21] , and a study of etanercept actually found previous exposure to improve drug survival [22] . For the base case, we assumed a dropout rate from biologic therapy of 20 % per year, which would closely reproduce the data from the largest of the registry studies (i.e., 40 % of patients were still on treatment at the end of 4 years) [19] . It was also assumed that ciclosporin (a drug included in best supportive care) would only be used for a maximum of 2 years based on published guidance [23, 24] . The model assumes that patients only receive benefits of treatment whilst receiving treatment, based on the clinical consensus that treatments do not alter the course of psoriasis and that continuous treatment is required to maintain disease control. In addition, patients entering the treatment period are assumed to maintain the level of response achieved during the trial period (i.e., they may make no further transitions between different levels of PASI response) until they either drop out or the 10-year time horizon ends. Sensitivity analysis around this assumption as well as the annual dropout rate was performed.
Health-Related Quality of Life
Achievement of different levels of PASI response and associated utility gain were used in the model to determine the impact of biological therapy on overall health. Base case estimates of utility gain were taken from the costutility analysis conducted by Woolacott and colleagues [8] , who estimated mean utility gain for two groups: ''all patients'' regardless of baseline quality of life, and for a subgroup of patients with the worst baseline quality of life (fourth quartile DLQI). They derived values by way of a two-stage linear regression analysis using data from three etanercept regulatory trials in psoriasis and the Health Outcomes Data Repository (HODaR) Database [25] . In the first stage, Woolacott and colleagues estimated the mean change in the DLQI score between baseline and week 12 for patients from etanercept trials who achieved different levels of PASI response and had different baseline DLQI scores. In the second stage, an ordinary least-squares linear regression analysis of the DLQI and EuroQol-5D (EQ-5d) data from the HODaR database was undertaken to ''map'' changes in DLQI associated with PASI responses to changes in EQ-5D utility. The mean utility gains for the all patients group were used in the base case (see Table 2 ) and gains for those with the worst baseline DLQI were used in a sensitivity analysis. This indirect utility model has been repeated in other populations [26] , but is criticised for its relatively poor fit to the data. A recent registry-based study in Sweden concluded that although correlation between EQ-5D, DLQI, and PASI was moderate to weak, if EQ-5D is not included as an outcome in the original trial, mapping is the next-best alternative [27] . Utility gain estimates that were derived in a similar fashion and used in other models [3, 4] informing NICE guidance were used in sensitivity analysis (see supplementary appendix).
Resource Use and Costs
Only direct healthcare costs were assessed, and these included the cost of drugs and their administration and monitoring and the cost of outpatient visits, dermatology day centre visits, and inpatient stays. The cost of tests undertaken to screen patients for eligibility of treatment was excluded from the analysis. Also excluded were the costs of treating adverse events, because of a lack of data of their impact on treatment pathways and resource use. Drug dosages, administration schedules, and unit costs of biologic and nonbiologic therapies were based on information from the British National Formulary 68 [28] ( Table 3 ). The frequency of monitoring and unit costs of [29, 30] Phototherapy session £91.90 [29, 30] Day centre visit £390.21 [29, 30] Inpatient hospitalisation £6,070.23 [29, 30] CrI credible interval, PASI Psoriasis Area and Severity Index, PASI50 reduction of at least 50 % in baseline PASI score, CI confidence interval, DLQI Dermatology Life Quality Index different laboratory tests were sourced from a previous economic evaluation [8] or from NHS reference costs [29] and inflated to 2013-14 values using the Hospital and Community Health Services inflation index [30] . The unit costs for inpatient stays, outpatient consultations, phototherapy, and dermatology day care centre visits were each calculated as a weighted mean based on activity levels of several NHS reference cost components [29] (see Table 2 ). Further details on resource use and unit costs are provided in the supplementary appendix.
Best Supportive Care
It is recognised that when patients in the UK NHS become eligible for a first biologic therapy, they must have exhausted or be intolerant to treatment options such as conventional systemic therapies (e.g., methotrexate and ciclosporin) and phototherapy, including PUVA [1] [2] [3] [4] . The guideline panel considered that although these therapies had either proven ineffective or given rise to certain toxicities, the patients for whom a second biologic was being considered were unlikely to go without treatment altogether. After all, these patients tend to have more severe disease than biologic-naive patients, as demonstrated by subgroup data from the PHOENIX1 and PHOENIX2 trials where patients with previous exposure to biologics reported higher PASI and DLQI scores and greater body surface area affected at baseline [14, 15] . In the absence of a second biologic therapy, these patients would likely be cycled through different modalities, accepting the associated risks. On this basis, the cost-effectiveness model has attempted to approach the treatments comprising ''best supportive care'' in a pragmatic fashion, albeit with limitations.
The working definition of best supportive care, in the context of patients with moderate to very severe plaque psoriasis who are being considered for further biologic therapy, is summarised in terms of resource use in Table 4 . This is based on the results of two cohort studies [31, 32] of high need psoriasis patients in the UK and in the Netherlands and supplemented by the clinical experience and opinion of the guideline panel. This diverse package of services, which includes drug treatment with methotrexate or ciclosporin, phototherapy, and specialist topical therapies delivered in dermatology day centres and inpatient care, is expected to cost an annual £11,436. Because of substantial uncertainties in these model parameters, they were subject to extensive sensitivity analyses.
Biologic Therapies
NICE guidance [1] [2] [3] [4] has stipulated that biologic therapies should be trialled for a given number of weeks and discontinued if an adequate response has not been observed. The recommended trial period varies between drugs: 12 weeks for etanercept, 10 weeks for infliximab, and 16 weeks for both adalimumab and ustekinumab. Because a class effect was being assumed for biologic therapy, the mean of these different trial lengths (13.5 weeks) was assumed. This should not affect the costs for drugs like infliximab and ustekinumab, although it might slightly overestimate the costs for etanercept and underestimate the costs for adalimumab. Similarly, using a 13.5-week trial period may underestimate benefits for drugs such as adalimumab and ustekinumab because nonresponding patients are forced to stop slightly earlier, but it will overestimate benefits for drugs such as infliximab and etanercept because it would mean that patients who should have stopped will continue to accrue benefits. Overall, the costs and benefits are expected to even out using an average 13.5-week trial period.
In addition to the cost of biologic drugs and their monitoring and administration, patients are expected to have four outpatient visits with a consultant dermatologist. It is also expected that whilst successful treatment will reduce the need for hospitalisations, it will not eliminate it [31, 32] . The base case assumes that the risk of hospitalisation is reduced by 76 % per annum following response to biologics [31] ; this is varied in sensitivity analysis. The total 13.5-week trial period cost for each biologic agent is presented in Table 5 . The average across all biologics for the trial period is £4,061. The total annual treatment period cost for each biologic agent, ciclosporin and methotrexate is presented in Table 5 . The average annual cost across all biologics for the treatment period is £12,456.
Sensitivity Analyses
The base case analysis outlined in the preceding sections is based on very limited evidence of effectiveness and cost. As such, there are substantial uncertainties around which sensitivity and scenario analyses are best suited to explore. These additional analyses focused around three main areas of uncertainty: variables associated with biologic therapy (i.e., stopping rules, dropout rates, distribution between agents, and extrapolation of treatment effects); variables associated with best supportive care (i.e., efficacy and resource use); quality of life data. A description of each sensitivity analysis performed is presented in the supplementary appendix.
All analyses were conducted in a probabilistic framework, thus capturing the imprecision and uncertainty around parameter point estimates. Probability distributions were based on error estimates from data sources, such as confidence intervals. Uncertainty in the probabilities of response were obtained directly from the joint posterior distributions of the Markov Chain Monte Carlo analysis in WinBUGS, thus preserving any correlations in the outputs. Beta distributions were used for other probabilities; gamma distributions, for resource use and disutility values; lognormal distributions, for NHS reference costs (see supplementary appendix). The results of 10,000 simulations are summarised as mean costs, mean QALYs, and the probability biologic therapy is most cost effective.
Model Validation
The model was developed in consultation with the NICE guideline panel of clinical experts and patient representatives. Model structure, inputs, and results were presented to the panel and discussed for clinical validation and interpretation. In addition, the model was systematically checked by the health economist undertaking the analysis; this included inputting null and extreme values and checking that results were plausible given inputs. The 
Results
Base Case
Results indicate that switching to a second biologic following intolerance to or failure of a first biologic is likely to cost £5,747 (95 % CI: £4,644 to £6,932) more over 10 years than switching immediately to the best supportive care, but this cost is likely to be offset by a 0.325 (0.124-0.793) gain in QALYs. The incremental costeffectiveness ratio (ICER) of a second biologic compared to the best supportive care is £17,681 per QALY. Results of the incremental analysis of results are presented in Table 6 and total costs disaggregated by type of resource use are presented in Fig. 2 . Whilst the probabilistic analysis demonstrates further biologic therapy to be associated with both significantly higher costs and greater benefits than best supportive care, it reveals a degree uncertainty in the decision between strategies. Further biologic therapy has a 50 % probability of being more cost effective than no further biologic therapy at willingness-to-pay thresholds of £20,000, and this probability rises to 84 % when the threshold increases to £30,000 (see Fig. 3 ).
Sensitivity Analyses
Given the paucity and limitations of evidence used to parameterise the model, extensive sensitivity and scenario analyses were used to explore the impact of variation in key inputs and to test alternative assumptions. Results of these analyses indicate that the incremental cost effectiveness of biologic therapy is particularly sensitive to alternative assumptions relating to the cost and annual dropout rates of biologic therapies, the efficacy of best supportive care, and the likelihood of hospitalisation and length of inpatient stay (see Table 7 ).
The base case assumed a class effect for biologic therapies and therefore took an average cost across adalimumab, etanercept, infliximab, and ustekinumab. Because the only efficacy data available were for infliximab and ustekinumab, we performed a series of sensitivity analyses restricting costs to just these agents. If only infliximab and ustekinumab are included, then the ICER increases to £27,781 per QALY. This is largely driven by the higher [28] b See [29] c See [8, 30] CI confidence interval, QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio Sequential Biological Therapy for Severe Psoriasis: A Cost-Effectiveness Analysiscosts associated with infliximab, best illustrated by results when only infliximab or only ustekinumab is modelled (ICERs equal £42,201 and £13,110, respectively). The evidence on drug survival for biologic therapies in this population was limited and conflicting. Sensitivity analysis showed that results were quite sensitive to variation in this parameter. A threshold analysis indicated that the ICER for further biologic therapy remains below £20,000 per QALY if dropouts are \35 % per year and below £30,000 per QALY if dropouts are less than 66 % per year. The model was also run for shorter time horizons in order to reduce the degree of extrapolation required beyond the trial period for which RCT evidence is available. The cost effectiveness of biologic therapy improves with shorter time horizons because fewer patients will have had time to drop out and switch over to best supportive care. An analysis was also performed to test the impact of assuming responses at the end of the trial period were maintained in the treatment period. Here, 40 % of patients were assumed to drop down a PASI response category each year before discontinuing when they dropped to below PASI50. Changing this assumption had very little impact on the base case results.
The hospitalisation rate among patients on further biologic therapy was assumed to be 76 % lower than for patients receiving best supportive care based on data from Fonia and colleagues [31] . Driessen and colleagues [32] reported a smaller reduction of 64 %, which was tested along with a 100 % reduction. A threshold analysis indicated that so long as biologics reduce hospitalisations by at least 51 %, then biologic therapy is expected to be cost effective at a threshold of £30,000 per QALY.
Results are most sensitive to changes in estimates of effect and assumed resource use of best supportive care ( Table 7 ). The base case assumed that best supportive care was only as effective as the placebo arms of the included clinical trials, a conservative assumption given the complex and interdependent nature of the treatments included in best supportive care. When more patients are assumed to respond (65 or 83 % achieving PASI50) to treatments included in best supportive care, such as inpatient care [33] , the ICER for further biologic therapy increases and its probability of being optimal is substantially reduced. The cost effectiveness of switching to a second biologic improves if mean length of stay per hospital admission increases and if a greater proportion of patients are classified as very high need (thus requiring more inpatient admissions per year). However, the likelihood of a second biologic being cost effective decreases as the proportion of very high need patients decreases, the number or length of hospitalisations decreases, or if the other types of care in best supportive care are removed and costs reduced (i.e., no UVB, no day centre, no drugs).
Base case results are relatively insensitive to changes in quality of life estimates, although sequential biologic therapy is more cost effective using utility values for patients with the worst DLQI at baseline (i.e., the greatest disease severity).
Discussion
This study performed a cost-effectiveness analysis of biologic therapy in patients with moderate to severe psoriasis who have not responded to, lost response to, or been intolerant to a first biological drug. The model was adapted from published analyses [8, 34] assessing the value of biologic therapies in biologic-naive patients. The analysis suggests that switching to an alternative biological drug may be more cost effective than moving to best supportive care without biological therapy, but most parameters in the model are highly uncertain, even unknown, making the analysis quite exploratory and interpretation challenging. The clinical evidence for biological treatments evaluated in this population is limited, although it clearly shows there to be a benefit compared to placebo. However, in reality, this population would never receive a placebo like in a clinical trial. Based on the NICE eligibility criteria for biological therapy, these patients will have failed to respond to or will have been intolerant to conventional systemic therapies (methotrexate and ciclosporin), thus limiting their further management options dramatically. In the absence of biologic therapy, they would likely receive a package of care with multiple components including specialist outpatient treatments and inpatient care, which may or may not produce treatment response and associated quality of life benefits. Defining this package of care was a significant challenge, and the analysis relied on a mixture of evidence from recent cost analyses [31] [32] [33] and clinical expert opinion. Indeed, efficacy and resource use associated with best supportive care in the absence of biologic therapy were among the most significant drivers of uncertainty in the analysis. Sensitivity analysis showed that when best supportive care resource use was intensified from base case assumptions, with a higher proportion of very high need patients, then the ICER decreased to just over £11,000. However, when the intensity of resource use for best supportive care was scaled back (i.e., fewer annual hospitalisations, shorter length of stay, and/or less outpatient day care), a second biologic therapy was less likely to represent better value for NHS resources. When best supportive care resource use was at its most limited (i.e., no hospitalisations), the ICER for sequential biologic therapy was more than £60,000. Results showed that only in the treatment of patients with the worst baseline quality of life (and hence the most to gain from successful treatment) would the substantial additional cost of delivering biological therapy compared to a less resource-intensive best supportive care be offset.
There was also significant uncertainty in the effectiveness of this newly defined best supportive care. Previous analyses have used the placebo response rates from RCT evidence, which are virtually equivalent to assuming no response at all. This was varied upward based on observational data from the UK, which showed that response to inpatient treatment ranged between 65 and 83 %. When inpatient treatment was assumed to be as effective as this, then the ICER of switching to an alternative biological therapy increased beyond the £30,000 per QALY gained threshold. Although quality of life gains are generally attached only to the clinical outcomes (i.e., PASI response, change in DLQI), the guideline panel discussed whether gains might be affected by how the outcome was achieved. The clinicians along with the patient representatives considered that although 3 weeks in hospital may induce an adequate level of response (PASI50), this could have a substantial negative impact on a patient's quality of life compared to a once or twice weekly injection or even an infusion every few months. Furthermore, in order to maintain that level of response, patients would likely have to carry on with regular outpatient day care appointments or use drug treatments that have failed in the past or have potentially serious adverse events (e.g., renal impairment or hepatotoxicity).
The results of this evaluation should be considered in light of several limitations related to a relative paucity of clinical and economic data available for this subgroup of psoriasis patients. First, the model includes a potentially heterogeneous population of patients with a variety of reasons for undergoing treatment with a second biologic therapy. The reason why the patient failed the first course of therapy may have an impact on the efficacy and potential value of the next treatment, although due to a lack of data, that was not captured here. Second, we assumed a class effect for all biologic therapies, although placebocontrolled RCT evidence in this patient subgroup is only available for infliximab and ustekinumab. It is unclear whether this approach overestimates or underestimates the likelihood of response with etanercept and adalimumab in this subgroup of patients, though the ACCEPT subgroup analysis failed to show a difference between ustekinumab and etanercept [16] . The base case result almost certainly underestimates the value of ustekinumab, because a sensitivity analysis showed that if this analysis were restricted to ustekinumab only, then further biologic treatment is likely to be cost effective (ICER = £13,110). Third, and as outlined in previous appraisals of biological therapy, there is relatively limited long-term experience with biological therapies, so that estimates of dropout and sustained response are quite uncertain. A threshold analysis showed that if the dropout rate is more than 66 % per annum, then further biologic therapy is unlikely to represent good value for NHS resources. Finally, there is limited data on adverse events, both in terms of their incidence as well as their impact on resource use and quality of life. They were not explicitly modelled, although they would certainly count amongst treatment dropouts, and we believe that their inclusion would not affect the conclusions of our analysis.
Based on the results of this analysis, several areas of research are urgently required so that future technology assessments are based on better data and fewer assumptions. More studies estimating the healthcare resource use of patients with severe and very severe psoriasis, both in the presence and absence of biologic therapies, would be useful to inform the cost side of the cost-effectiveness equation. Similarly, with increasing numbers of psoriasis patients now exposed to biologic therapies, RCTs evaluating the performance of sequential biologic therapy in the minority for whom they fail are needed to identify optimal sequences. Finally, better data on the longer-term response and discontinuation of biologic agents in psoriasis are needed to improve on the assumptions currently employed in virtually all economic evaluations in this area.
Conclusions
This study serves as an initial investigation of the potential cost effectiveness of further biologic therapy for patients with chronic plaque psoriasis that were previously treated with biologic therapy. Sensitivity analysis highlighted the model variables that have a significant individual and collective impact on the results, namely the efficacy of treatments and elements of resource use, especially hospitalisations. Given the considerable uncertainty in the results, further studies should be designed and subgroup analyses planned to evaluate the clinical efficacy of biologic therapies. Particular attention should be given to short-term and longer-term responses as well as their impacts on healthcare resource use.
